Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT04821843

Neoadjuvant Treatment Modalities in Esophageal Cancer

Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-01-21

2000

Participants Needed

1

Research Sites

1513 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year. Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as efficatious therapy to improve patients outcomes in esophageal or esophagogastric junction cancer as compared with surgery alone. The purpose of this study was to explore the optimal neoadjuvant treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with esophageal or esophagogastric junction cancer.

CONDITIONS

Official Title

Neoadjuvant Treatment Modalities in Esophageal Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years or older
  • Diagnosed with esophageal or esophagogastric junction cancer
  • Histologically confirmed squamous cell carcinoma or adenocarcinoma staged I-IVa (AJCC 8th edition)
  • Primary treatment planned at Cancer Hospital, Chinese Academy of Medical Sciences
  • ECOG performance status score of 0 or 1
  • Estimated survival time of at least 3 months
  • Normal organ and marrow function as indicated by: hemoglobin 2100 g/L, leukocytes 24000 G/L, neutrophils 2000 G/L, platelets 10,000/mm3, creatinine 1.5 times upper limit or CCR 60 ml/min, AST/ALT 2.5 times upper limit, total bilirubin 1.5 times upper limit, INR 1.5 times upper limit, APTT 1.5 times upper limit, PT 1.5 times upper limit
  • Provided informed consent
Not Eligible

You will not qualify if you...

  • Presence of distant metastasis beyond regional lymph nodes or in liver, lung, bone, CNS, etc.
  • History of other cancers within 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer
  • Active infections such as tuberculosis or hepatitis
  • History of myocardial infarction within past 6 months or ventricular arrhythmia
  • Uncontrolled illnesses including active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness
  • Allergic reactions to paclitaxel, albumin, or cisplatin
  • Participation in other clinical trials currently or within 4 weeks prior
  • Pregnant or breastfeeding females
  • Lack of medical records

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)

Beijing, China, 100021

Actively Recruiting

Loading map...

Research Team

X

Xin Wang, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here